The role of serine/threonine phosphatases in human development: Evidence from congenital disorders

Pieter Vaneynde1,2, Iris Verbinnen1,2 and Veerle Janssens1*,2

1Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Leuven, Belgium, 2Leuven Brain Institute (LBI), Leuven, Belgium

Reversible protein phosphorylation is a fundamental regulation mechanism in eukaryotic cell and organismal physiology, and in human health and disease. Until recently, and unlike protein kinases, mutations in serine/threonine protein phosphatases (PSP) had not been commonly associated with disorders of human development. Here, we have summarized the current knowledge on congenital diseases caused by mutations, inherited or de novo, in one of 38 human PSP genes, encoding a monomeric phosphatase or a catalytic subunit of a multimeric phosphatase. In addition, we highlight similar pathogenic mutations in genes encoding a specific regulatory subunit of a multimeric PSP. Overall, we describe 19 affected genes, and find that most pathogenic variants are loss-of-function, with just a few examples of gain-of-function alterations. Moreover, despite their widespread tissue expression, the large majority of congenital PSP disorders are characterised by brain-specific abnormalities, suggesting a generalized, major role for PSPs in brain development and function. However, even if the pathogenic mechanisms are relatively well understood for a small number of PSP disorders, this knowledge is still incomplete for most of them, and the further identification of downstream targets and effectors of the affected PSPs is eagerly awaited through studies in appropriate in vitro and in vivo disease models. Such lacking studies could elucidate the exact mechanisms through which these diseases act, and possibly open up new therapeutic avenues.

KEYWORDS
serine/threonine protein phosphatase, de novo mutation, congenital disease, neurodevelopmental disorders, sex development disorder

1 Introduction

Reversible protein phosphorylation lies at the core of protein regulation, fine-tuning their activity and stability in cells and tissues. Through addition or removal of a negatively charged phosphate group, protein activity can be up- or downregulated, or their stability promoted or inhibited. In homeostatic conditions, a delicate
FIGURE 1
Structure of Protein Serine/Threonine phosphatase (PSP) superfamily. (A) Structural and domain organisation of the catalytic subunits of the main PSP phosphatases. PSPs can be subdivided into three subfamilies, the Phosphoprotein phosphatases (PPP), the Metal-dependent phosphatases (PPM), and the Haloacid phosphatases (HAD). The central part of each PSP phosphatase denotes the catalytic core domain, with relevant conserved amino acids and their position annotated. A red amino acid denotes involvement in metal binding; blue denotes phosphate binding. Additional structural and regulatory domains are indicated as follows: CaM BD, Ca²⁺-calmodulin binding domain; AID, auto-inhibitory domain; TPR domain, tetratricopeptide domain; EF-hands, canonical Ca²⁺-binding motif; RA-D, Ras-association domain; PH, Pleckstrin homology domain; LRR, leucine-rich repeat; PDZ-L, PDZ Ligand; BRCT domain, BRCA1-related C-terminal domain; TFIIF, transcription factor interacting helix. Bold indicates involvement in inborn genetic disease. (B) Organisation of PSP holoenzymes. PP1 forms a dimer between the catalytic subunit (3 isoforms), and regulatory PIPs (~180). PP2A predominantly forms trimers consisting of the catalytic subunit (3 isoforms), a Ca²⁺-binding regulatory subunit (2 isoforms) and CaM, Ca²⁺-calmodulin. PP4 and PP6, like PP2A, can form both dimers and trimers, with trimers consisting of the catalytic subunit (1 isoform each), a structural subunit (R, 3 isoforms each) and a regulatory subunit (R′, 2 and 3 isoforms, respectively), and dimers consisting of the catalytic and a structural subunit. PDP1 is the only non-PPP phosphatase that forms a holoenzyme with one regulatory subunit (R, 1 isoform). C, catalytic subunit; R, scaffold or regulatory subunit; R′, regulatory subunit; A, scaffold subunit of PP2A; B, regulatory subunit of PP2A; CaM, calmodulin.
phosphoproteomic balance is achieved through the counterbalanced action of phosphorylating kinases, and dephosphorylating phosphatases. Consequently, when this balance is disrupted, disease inevitably follows, making kinases and phosphatases prime therapeutic targets in cancer, neurodegenerative diseases, diabetes, cardiac diseases, immune dysfunction, development, and other human pathologies. As protein kinases were discovered several decades ahead of protein phosphatases, the latter enzymes generally lag a bit behind their enzymatic antagonists, both in terms of general understanding of their function and regulation, and in terms of their implication or therapeutic targeting in human disease (Brautigan, 2013; Tonks, 2013).

Regulatory phosphorylation occurs on either a serine, threonine, or tyrosine residue. Due to tyrosine having a benzene ring, and the similar structure between serine and threonine, two major classes of protein phosphatases have been identified, the serine/threonine phosphatases (PSP), and the protein tyrosine phosphatases (PTP). In this review, we will focus on the serine/threonine phosphatase family of proteins, highlighting their roles in inborn genetic disorders.

2 Structure and regulation of Ser/Thr phosphatases

PSP phosphatases specifically dephosphorylate phospho-Ser or phospho-Thr residues, which, throughout the proteome, represent the large majority of protein phosphorylation, with phospho-serine estimated 86.4% and phospho-threonine 11.8% (Olsen et al., 2006). In humans, PSP phosphatases consist of three distinct subfamilies, the phosphoprotein phosphatases (PPP), the metal-dependent protein phosphatases (PPM), and the Asp-based HaloAcid Dehalogenase (HAD) phosphatases – which largely differ from each other in their specific structures and catalytic mechanisms (Figure 1) (Shi, 2009; Janssens, 2021).

2.1 Phosphoprotein phosphatases

The subfamily of phosphoprotein phosphatases (PPP) are further subdivided into seven different classes, PP1 through PP7 (Figure 1A), all of which, but PP5 and PP7, form holoenzymes (Figure 1B).

The identification and characterization of PPPs took a flight in the 1990s, using novel genetic and molecular tools. Then, it was noticed that certain, sometimes unidentified, phosphatases contained several conserved elements, and could thus be grouped within the same family (Cohen, 1997). PPPs are characterised by several conserved amino acid sequences in their catalytic subunits, with certain residues responsible for metal binding, and others responsible for phosphate binding (Figure 1A) (Shi, 2009). The coordinated metal ions bind and activate a water molecule that performs the nucleophilic attack on the P-atom of the phosphate group to remove it from the substrate (Shi, 2009). In addition to the relatively conserved catalytic core domain, which entails the highly conserved metal- and phosphate-binding residues, other regulatory domains can be present (Figure 1A). PP3 (also called PP2B or calcineurin), for example, has an additional C-terminal extension, containing a calmodulin-binding domain, and an auto-inhibitory domain. The latter domain constitutively represses PP3 activity, but upon binding of Ca2+/calmodulin, PP3 becomes active (Roy and Cyert, 2020). PP5 also contains an auto-inhibitory domain located in the C-terminal extension, which holds the N-terminal extension in place to physically block the catalytic core domain. Upon binding of the tetratricopeptide domain within the N-terminal extension to a substrate, this inhibition gets lifted to allow dephosphorylation (Golden et al., 2008). PP7, also acting as a monomer, contains a calmodulin-binding domain as well, located in the N-terminal extension. Furthermore, in the C-terminal extension of PP7, EF-hands are present, providing an extra regulation of activity through Ca2+ (Shi, 2009).

The remaining PPPs – PP1, PP2A, PP4, and PP6 – lack any regulatory domains and rely on interaction with regulatory subunits for targeting and regulation of activity (Janssens, 2021) (Figure 1B). In addition, PP3 also forms a complex with one regulatory, Ca2+-binding subunit, despite having two regulatory domains itself (Figure 1B). PP1 binds a wide variety of regulatory subunits, called PP1-interacting proteins (PIPs), of which more than 180 are known and which act as targeting subunits, substrate specifiers, substrates, or inhibitors (Figure 1B). They combine short linear motifs (e.g. RVxF, SILK, MyPhoNE, ... ) to form large and unique interaction interfaces with PP1 (Verbinnen et al., 2017). Additionally, PP1 has been described to form trimers as well; however, this is less common than dimer formation (Verbinnen et al., 2017). PP2A on the other hand, mainly forms trimeric holoenzymes consisting of the catalytic C-subunit, a regulatory B-subunit and a scaffolding A-subunit (Figure 1B) (Janssens and Goris, 2001). Here, two isoforms of both the C- and the A-subunit are known, while 15 B-subunit encoding genes express over 25 B-subunit isoforms through alternative splicing/translation initiation, forming more than 100 trimers (Lambrecht et al., 2013). Furthermore, dimers of PP2A between the C- and A-subunit have been described, although to a lesser extent than trimers (Janssens and Goris, 2001). The B-subunits define substrate specificity of PP2A, in part by the presence of specific Short Linear Interaction Motifs (SLIMs) that function as substrate docking motifs (Cundell et al., 2016; Hertz et al., 2016; Kruse et al., 2020; Fowle et al., 2021). The
PP2A-related phosphatases PP4 and PP6 also form trimers and dimers, alike to PP2A (Figure 1B), but the overall number of holoenzyme complexes is significantly smaller (Ohama, 2019; Park and Lee, 2020).

### 2.2 Metal-dependent phosphatases

A second subfamily of PSPs are the PPMs, being magnesium/manganese ion-dependent in their phosphatase activity. The PPM subfamily can be further subdivided into the ‘classical’ PPMs, also called type 2C protein phosphatases (PP2C), the pleckstrin homology domain leucine-rich repeat protein phosphatases (PHLPP), and the pyruvate dehydrogenase phosphatases (PDPs). All these phosphatases share a conserved catalytic core region, with highly conserved amino acid sequences responsible for phosphate- or metal-binding (Figure 1A) (Shi, 2009). The PP2C family has thirteen members (PPM1A, PPM1B, PPM1D, PPM1E, PPM1F, PPM1G, PPM1H, PPM1J, PPM1K, PPM1L, PPM1M, PPM1N, and PPM1O, also known as ILKAP) which are highly similar but differ in substrate specificity and activity (Kamada et al., 2020). The PHLPPs and PDPs each consist of two members, PHLPP1 and PHLPP2, and PDP1 and PDP2. As the only member of the PPM superfamily to form holoenzymes, PDP1 forms a dimer with a regulatory subunit (Figure 1B) (Janssens, 2021). PHLPPs contain several regulatory domains within the protein structure, such as the pleckstrin homology domain, the RAS-association domain, and leucine-rich repeats in the N-terminal extension, and the PDZ-ligand in the C-terminal extension (Figure 1A) (Baffi et al., 2021).

### 2.3 Haloacid dehalogenase phosphatases

The third PSP subfamily of HAD phosphatases contains seven members (CTDPI, CTDSP1, CTDSP2, CTDSPL, CTDSPL2, CTDNEP1, and UBLCP1) sharing a conserved structural organisation in the catalytic core. Here again, highly conserved amino acids within this family of phosphatases bind metal-ions and phosphates necessary for phosphatase activity (Figure 1A) (Shi, 2009). HADs use an aspartate residue for nucleophilic attack, in contrast to the classical serine or cysteine residue (Shi, 2009). As such, HADs are unique in their enzymatic activity, explaining their lack of targeting by commonly used phosphatase inhibitors (Seifried et al., 2013). Structurally, the HAD catalytic core is arranged as a modified Rossmann fold, with additionally three structural signatures (cap, flap, and squiggle domain) that confer substrate specificity (Seifried et al., 2013). FCP1, encoded by CTDPI, contains several structural domains, such as an insertion in the catalytic core, a BRCA1-related C-terminal domain (BRCT), and a transcription factor interacting helix (TFIIF), important in substrate binding and thus phosphatase activity (Figure 1A).

### 3 Ser/Thr phosphatases in congenital diseases

The role of PSP phosphatases in inborn developmental disorders has only recently emerged, in part, thanks to major advancements in genetic technologies such as Next Generation Sequencing (NGS), and in part through emerging insights into the role of de novo mutations in genetic disease (Veltman and Brunner, 2012; de Ligt et al., 2013). These advancements lowered the cost of routinely screening for genetic alterations throughout the exome, and even through the whole genome, at base pair resolution, leading to a major expansion of novel congenital causes of disease. In particular, the application of so-called ‘ trio sequencing’ methodology underscored the important role of germline de novo point mutations as major causes of rare sporadic monogenic diseases (Vissers et al., 2010; Gilissen et al., 2014).

Recently, many new initiatives have been taken to focus on deciphering until then unknown causes of disease. A prime example is the Deciphering Developmental Disorders (DDD) study in the United Kingdom, having screened over 33,000 parents and children as of January 2020, leading to the identification of 67 completely new disorders, including several involving phosphatase genes (Deciphering Developmental Disorders Study, 2015; Short et al., 2018; Wright et al., 2018; Kaplanis et al., 2020). This example highlights the explosion of newly identified genetic disorders during recent years, many of which linked to phosphatase dysfunction, and creating the need for more research into this subject.

In this review, we aim to create an overview of currently known, inborn genetic diseases caused by mutations in PSP phosphatase genes. Thus, we aim to provide a reference framework to further study these novel genetic disorders, and spur advancement in mechanistic insight in these diseases.

### 3.1 PPPs

#### 3.1.1 Protein Phosphatase 1

PP1 phosphatases form a myriad of holoenzyme complexes, with a diverse set of regulatory subunits or PIPs (Verbinnen et al., 2017). This way, PP1 can form more than 540 dimers, with an undefined number of trimers. Of the three catalytic subunit encoding genes, only PPP1CB has been defined as the cause of a congenital disease, i.e. Noonan-like syndrome with loose anagen hair-2. In addition, three major PP1 regulatory subunit genes also confer inborn disease upon mutation: PPP1R12A, PPP1R15B, and PPP1R21.
PP1 as a phosphatase is ubiquitously present in cells and tissues, and has many different functions, depending on localisation and expression of its regulatory subunit. In brain, expression of a constitutively active inhibitor of PP1, Inhibitor-1, improved learning and memory formation, while worsening recovery from ischemia-induced brain damage (Ferreira et al., 2019). Furthermore, in the striatum, PP1 is inhibited through DARPP-32 (dopamine and cAMP-regulated phosphoprotein of 32 kDa), a key player in dopamine signalling, when DARPP-32 is phosphorylated at Thr34 (Ferreira et al., 2019). Dysregulation of this inhibition is associated with several neurological and psychiatric diseases, such as Parkinson’s disease, drug addiction, and schizophrenia (Ferreira et al., 2019). The actin-binding PIPs, neurabin-1 and spinophilin, are required for neurite formation, target PP1 to post-synaptic densities, and regulate synaptic transmission and plasticity through regulation of AMPA- and NMDA-receptor dephosphorylation (Ferreira et al., 2019). The involvement of PPP1CB in Noonan syndrome-like disorders was first found in 2016, when four patients presented with typical symptoms of this disorder, including distinctive hair anomalies, developmental differences, and structural brain abnormalities (Gripp et al., 2016) (OMIM#617506). Typically, this disorder is caused by mutations in SHOC2, encoding a leucine-rich repeat scaffold protein, which in complex with PPP1-Cβ and MRAS, activates the RAS/MAPK pathway (Motta et al., 2019). As such, it came as no surprise that mutations in PPP1CB lead to similar phenotypes. The four initially identified patients showed a diverse phenotype, with symptoms including developmental delay, hypotonia, macrocephaly, a prominent forehead, and cerebellar abnormalities, among others. In this study, two de novo heterozygous variants were found, a Pro49Arg substitution.
and a Ala56Pro substitution (Gripp et al., 2016) (Figure 2). In the following years, a few more patients were identified, all carrying the heterozygous Pro49Arg substitution (Bertola et al., 2017; Zambrano et al., 2017; Maruwaka et al., 2022). Two years after initial reporting, Young et al. showed that mutations in PPP1CB, and other causative genes of this disorder, all promote formation of a ternary complex consisting of SHOC2, PP1-C, and MRAS (Young et al., 2018). In this ternary complex, SHOC2 acts as a structural subunit, holding together the regulatory MRAS and PP1-C subunit, leading to a very specific dephosphorylation of RAF kinases on an inhibitory site, and eventually, to overactivation of the MAPK pathway further downstream (Young et al., 2018). As such, gain-of-function (GOF) mutations in PPP1CB lead to Noonan syndrome-like disorders. Furthermore (other) mutations in PPP1CB have been implied as causative of intellectual disability and congenital heart disease. Ma et al. identified eight individuals with heterozygous, de novo variants in PPP1CB, presenting with intellectual disability, developmental delay, congenital heart disease, macrocephaly, short stature, and dysmorphic features (Ma et al., 2016). Five distinct variants were found, the Pro49Arg substitution, a Glu183 substitution to either a Val or Ala, a Thr254 substitution, an Ala274 substitution, and an Arg183 substitution (Gripp et al., 2016)(Figure 2). In the interaction between myosin and actin in smooth muscle cells, the holoenzyme regulates function of non-muscle myosin II, and MRAS malformations, or an overlap of both (Figure 2) (Hughes et al., 2020; Alkhunaizi and Chitayat, 2021)(OMIM#618820). Furthermore, a discordance between genotypic and phenotypic sex was observed in two individuals. The neurological phenotype includes, but is not limited to, brain malformations such as holoprosencephaly, macro- and microcephaly, dysmorphic facial features, seizures and a high frequency of developmental delay. Nine individuals presented with urogenital malformations, including malformations of the genitalia in both sexes, such as the presence of a uterus in XY individuals. No clear genotype-phenotype association could be established, given the wide diversity of phenotypic features, and the variants being spread among multiple exons and domains (Figure 2). However, all variants are likely loss-of-function due to premature stop codon gains, canonical splice acceptor site loss, or framshifts followed by premature translation stops, in agreement with what authors concluded (Hughes et al., 2020), although no functional studies were performed to confirm this. The authors did nicely show expression of PPI12A in mouse embryonic brain tissue, and presence of MYPT1 in the developing lower urinary tract tissues (Hughes et al., 2020), consistent with its presumed role in embryogenesis of the brain and the genitourinary systems, and in sex development. Thus, further investigation of these twelve variants is warranted to conclusively prove loss-of-function, and to identify affected pathways caused by variations in PPI12A.

The ubiquitously expressed PPI15B gene, encoding the Constitutive Repressor of eIF2a phosphorylation (CRoP), is involved in protein kinase R-like endoplasmic reticulum kinase (PERK) signalling. PERK itself phosphorylates eukaryotic translation initiation factor 2a (eIF2a), thus downregulating protein translation (Abdulkarim et al., 2015). This signalling pathway is of importance in regulating stress on the endoplasmic reticulum, caused by an imbalance in unfolded protein load and the endoplasmic reticulum’s functional capacity. CRoP continuously dephosphorylates eIF2a in basal conditions, thus allowing eIF2a to carry out its function as translation initiator. When the unfolded protein load becomes too large, PERK is activated, leading to phosphorylation and inhibition of eIF2a, thus lowering unfolded protein load in the endoplasmic reticulum (Abdulkarim et al., 2015). In 2015, two independent groups found a homozygous mutation in PPI15B, leading to a change of Arginine 658 to a Cysteine in four patients, of which two sets of siblings (Abdulkarim et al., 2015; Kernohan et al., 2015) (OMIM#616817). The Arg658Cys
substitution is located in the conserved C-terminal functional core of the protein, near the RVSF-motif (Figure 2). This C-terminal core directs interaction between CReP and PP1 and mediates substrate specificity (Abdulkarim et al., 2015). All four patients present with neonatal-onset diabetes, short stature, microcephaly, and intellectual disability. Interestingly, homozygous loss-of-function mutations in EIF2AK3, encoding PERK, cause a similar phenotype, i.e. Wolcott-Rallison syndrome (OMIM#226980), characterized by neonatal diabetes associated with skeletal dysplasia and/or episodes of acute liver failure (Délepine et al., 2000; Biason-Lauer et al., 2002). This implies PPP1R15B mutations to be involved in PERK signalling and elF2a dysphosphorylation. Accordingly, the p.Arg658Cys variant of CReP led to loss of PP1 catalytic subunit binding, in both patient-derived lymphoblasts and in a HEK293T overexpression model. As a consequence, increased constitutive phosphorylation of elF2a was observed (Abdulkarim et al., 2015; Kernohan et al., 2015). Furthermore, it was shown that PPP1R15B was induced after ER stress in pancreatic β-cells in a PERK-dependent fashion, whereas silencing of PPP1R15B led to higher levels of elF2a phosphorylation (Abdulkarim et al., 2015). Additionally, insulin secretion was impaired by PPP1R15B deficiency in β-cells, which then became sensitised to apoptosis (Abdulkarim et al., 2015).

Lastly, RNA and protein levels of PPP1R15B were increased in patient-derived lymphoblasts, indicating a compensatory increase in expression to try to ameliorate the effects of CReP deficiency (Kernohan et al., 2015). Taken together, these data strongly implicate the p.Arg658Cys variant of CReP in altering PERK signalling and being deleterious to pancreatic β-cells (and likely other secretory tissues), resulting in long lasting, early-onset diabetes. As of yet, it remains unclear how PPP1R15B loss-of-function explains the short stature and brain-related phenotypes observed in affected patients.

Although PPP1R21 is ubiquitously and highly expressed in most tissues (Uhlén et al., 2015; Karlsson et al., 2021), its function remains poorly understood. As a PP1 regulatory subunit, PP1-R21 plays a role in endosome formation, and co-localises with the early endosome marker EEA1. The same study showed that PPP1R21 plays a role in endosome formation, and co-localises with the late endosome marker LAMP2 (Figure 3). It was induced after ER stress in pancreatic β-cells (and likely other secretory tissues), resulting in long lasting, early-onset diabetes. As of yet, it remains unclear how PPP1R15B loss-of-function explains the short stature and brain-related phenotypes observed in affected patients. One study performed deeper analysis of one variant, finding that expression of PPP1R21 in patient-derived fibroblasts was lacking, and no protein could be observed, thus confirming that the variant was a null allele (Rehman et al., 2019). As PP1-R21 co-localises with an early endosome marker, the authors tested whether the uptake and clearance of transferrin-488 was affected in patient-derived fibroblasts and found that macro-autophagy is not disturbed by variants of PPP1R21, while clearance was mildly delayed. Furthermore, electron microscopy revealed a mild endolysosomal dysfunction, by nature of an increase in myelin figures in patient-derived fibroblasts (Rehman et al., 2019). Of note is that the authors only performed experiments with fibroblasts derived from one patient, carrying the p.Leu536Phefs*7 variant, which should be noted as a limitation of the study. Due to the poorly understood function of PP1-R21, no further molecular studies can be performed, such as dephosphorylation assays of a common substrate. Therefore, it is necessary to first understand the molecular and functional characteristics of PP1-R21, in order to understand the exact effect of variants in PPP1R21 on cellular and brain function.

3.1.2 Protein Phosphatase 2A

3.1.2.1 PP2A-related neurodevelopmental disorders

PP2A phosphatases are holoenzymes, in most cases consisting of three distinct subunits: a scaffolding A-subunit, a catalytic C-subunit, and a regulatory B-subunit (Figure 1B). The genetic complexity of this phosphatase family in humans is high, as both the A- and C- subunits are encoded by two genes (PPP2R1A, PPP2R1B, and PPP2CA and PPP2CB, respectively), and the variable B-subunits, belonging to four different families, are encoded by 15 distinct genes: PPP2R2A, PPP2R2B, PPP2R2C, PPP2R2D (R2, B, PR55 or B55 family); PPP2R3A, PPP2R3B, PPP2R3C (R3, B″ or PR72 family); PPP2R5A, PPP2R5B, PPP2R5C, PPP2R5D, PPP2R5E (R5 or B', PR61 or B56 family); and PPP2R6A, PPP2R6B and PPP2R6C (R6, B″ or striatin family). This diversity in subunits results in more than 100 possible PP2A trimers, in which the B-subunit confers substrate specificity and localisation, the C-subunit catalytic activity, and the A-subunit structural integrity (Janssens and Goris, 2001; Reynhout and Janssens, 2019).

Due to the omnipresence of PP2A in human cells, making up to 1% of the total cellular protein content (Remmerie and Janssens, 2019), PP2A is involved in a wide variety of cellular pathways and physiologic functions (Janssens and Goris, 2001; Reynhout and Janssens, 2019). Among the PP2A-regulated pathways are PI3K-Akt, mTOR, MAPK, Wnt, apoptosis, cell cycle control, and DNA damage response (Remmerie and
Given this wide variety of signalling pathways regulated by PP2A, it has been difficult to exactly delineate which pathway is under control of what regulatory subunit, as well as the exact effect of changes in PP2A function on signalling outcome. Thus far, most PP2A research has been performed in a cancer-context, where the large majority of PP2A trimers act as tumour suppressors (Meeusen and Janssens, 2018; Remmerie and Janssens, 2019). Since 2015, however, de novo mutations in several PP2A genes have been implicated as causative for neurodevelopmental or other inborn brain disorders (Houge et al., 2015; Loveday et al., 2015; Sandal et al., 2021; Verbinnen et al., 2021), while some inherited mutations in other PP2A genes mainly affected development of other organs (Guran et al., 2019). Specifically, PP2A-related neurodevelopmental disorders are characterized by mutations in PPP2RIA (Aα), PPP2CA (Ca), PPP2RC (B55γ), PPP2R5B (B56β), PPP2R5C (B56γ), and PPP2R5D (B56δ), with most patients and mutations, so far, found in PPP2R5D (Figures 3A–C). Currently, more than 260 patients have been identified, while still more cases are being reported in literature, and more patients are being diagnosed every month (https://jordansguardianangels.org/). In contrast, mutations in PPP2R3C (encoding the regulatory B″γ or G5PR subunit) were found to be mainly associated with deficits in gonadal development (Guran et al., 2019) (Figure 3D), and mutations in the promoter of PPP2R2B (encoding B55δ) with spinocerebellar ataxia (Holmes et al., 1999).

PPP2CA and PPP2R1A

PP2A A- and C-subunit expression is high in both developing and adult brain tissue, with a higher expression of PPP2R1A and PPP2CA as compared with their β isoform encoding genes, PPP2R1B and PPP2CB (Verbinnen et al., 2021). As such, PP2A has been shown to be important in brain development and function, with several mouse studies performed (Reynhout and Janssens, 2019; Verbinnen et al., 2021). Brain-specific PP2A Ca knockout in mice has been linked to microcephaly and cortical atrophy, while learning and memory was also impaired (Liu et al., 2018). Of note, a complete Ppp2ca or Pp2r1a knockout in mice is embryonically
lethal around E5.5-E6, due to impaired gastrulation and lack of mesoderm formation (Götz et al., 1998; Lange et al., 2017).

Fifteen heterozygous, de novo variants affecting PPP2CA have thus far been identified in sixteen individuals with a neurodevelopmental disorder, of which one full gene deletion, one insertion, four nonsense variants, and nine missense variants (Figure 3A) (Reynhout et al., 2019) (OMIM#618354). Patients presented with a heterogeneous set of symptoms, including mild to severe intellectual disability and developmental delay, autism spectrum disorder, seizures and brain abnormalities (Reynhout et al., 2019). Biochemical characterisation of the insertion, nonsense and missense variants revealed mainly loss-of-function, consistent with haploinsufficiency for milder cases, and dominant-negative action for more severe cases (Reynhout et al., 2019). In the latter, catalytic activity of the variant was completely abolished, but holoenzyme formation with specific B subunits, mainly belonging to the B56 family, was retained (Reynhout et al., 2019).

In PPP2R1A, 18 distinct heterozygous, de novo mutations have been found in 41 cases thus far (Figure 3A) (Houge et al., 2015; Wallace et al., 2019; Zhang et al., 2020; Lenaerts et al., 2021; Baker et al., 2022; Douzgou et al., 2022) (OMIM#616362). Here, patients can be classified into at least two clinical subsets, one milder and one more severe group. Both groups display typical PP2A-related neurodevelopmental symptoms such as hypotonia, intellectual disability and developmental delay. However, the mild subgroup of individuals tends to have macrocephaly, no epilepsy, and sometimes, microtia and loss of hearing, while patients in the severe subgroup tend to present with microcephaly, seizures, facial dysmorphisms, corpus callosum hypoplasia or agenesis, and sometimes, congenital heart defects (Lenaerts et al., 2021; Baker et al., 2022). Variants characterising the mild subgroup are located in HEAT–repeats 4 or 5 of the Aα subunit (Figure 3A), and show normal binding to B55 and Bδ, but severely decreased binding to B56 subunits apart from B56δ (Lenaerts et al., 2021). In contrast, variants in the severe subgroup are located in HEAT–repeats 5, 6 or 7, with severe impairment of B55 binding and variable binding defects of Bδ and B56, while Bδ and B56δ binding were retained (Lenaerts et al., 2021). One variant (p.Ser152Phe) did not show any PP2A activity, consistent with haploinsufficiency for milder cases, and dominant-negative action for more severe cases (Reynhout et al., 2019). All affected individuals were heterozygous carriers of a translocation disrupting two genes, the extracellular matrix-encoding component LAMA2 and PPP2R2C, encoding the PP2A B55γ subunit (Figure 3B). LAMA2 is found to be recessively involved in congenital muscular dystrophy type-1A, with heterozygous carriers being unaffected. Thus, the authors ascribed the reported phenotype to the disruption of PPP2R2C. Interestingly, PPP2R2C is not expressed during embryonic development, but Ppp2r2c is expressed in all regions of the forebrain in adult mice, with highest expression in the hippocampus, which is involved in learning (Backx et al., 2010). No further functional studies were performed to elucidate the exact mechanism of disease, providing opportunity to further study the function of PPP2R2C in brain.

PPP2RSD and PPP2R5C

PPP2R5D is highly expressed during embryogenesis and in the adult brain, indicating its important role (Verbinnen et al., 2021). During embryogenesis, it plays a role in the cell cycle, being a negative regulator of CDC25 phosphatase by targeting PP2A to the nucleus (Biswas et al., 2020). Furthermore, B5δ plays a role in striatal dopaminergic neurotransmission, neurotrophic signalling, and tau phosphorylation (Biswas et al., 2020). However, Ppp2r5d knockout in mice showed no brain abnormalities or memory and learning defects, but a tauropathy instead (Louis et al., 2011). Ppp2r5d heterozygous gene trapping, however, showed weakened pre-pulse inhibition, correlating with glycogen synthase kinase-3β hyperphosphorylation (Kapflhamer et al., 2010). Interestingly, the double knockout of Ppp2r5d and Ppp2r5c proved embryonic lethal at day E12, despite single knockouts being viable (Dyson et al., 2016).
et al., 2022), perhaps indicating a functional overlap and rescue of one subunit by the other. In dopamine signalling, B56δ has been shown to regulate dephosphorylation of DARPP-32, an important dopamine regulator and inhibitor of PP1 (Ahn et al., 2007). Furthermore, B56δ plays an indirect role in the phosphorylation of tau, a major factor in Alzheimer’s disease (Louis et al., 1999; Yu et al., 2014). As such, PPP2R5D plays an important role in several aspects of brain function, in various molecular pathways.

Patients with de novo variants of PPP2R5D most commonly present with intellectual and developmental delay, hypotonia, macrocephaly, distinct facial features (e.g. frontal bossing) and less common symptoms, such as epilepsy, autism spectrum disorder, ADHD and early-onset Parkinsonism (Houge et al., 2015; Loveday et al., 2015; Shang et al., 2016; Yeung et al., 2017; Mirzaa et al., 2019; Kim et al., 2020; Hetzelt et al., 2021; Walker et al., 2021; Yan et al., 2021; Oyama et al., 2022) (OMIM#616355). Thus far, seventeen variants have been reported for PPP2R5D which are spread throughout the whole protein, but some seem to cluster around a conserved acidic loop, or a canonical short linear interaction motif-binding site (Figure 3C) (Verbinnen et al., 2021). Current literature states that these de novo variants act in a dominant-negative fashion, showing decrease in both A- and C-subunit binding, thus potentially trapping the substrate (Houge et al., 2015). Recently, however, it was found that different variants affect formation of the holoenzyme differently, and three distinct biochemical groups were identified: one where only C-binding was affected, one where only a common SLIM-containing interactor was affected, and one where both were affected (Oyama et al., 2022). This nicely correlated with the clinical findings, where severity of the phenotype was less when both binding partners were affected. In contrast, in the two subgroups where only one of the two binding partners were affected, the phenotypes were found to be more severe, consistent with a stronger dominant-negative effect (Oyama et al., 2022).

However, downstream molecular effects of PPP2R5D mutations remain poorly understood, with one variant of B56δ (p.Glu420Lys) leading to a constitutive activation of the Akt-mTOR pathway when reconstituted in HEK293 cells (Papke et al., 2021). However, no other variants were tested, and the downstream molecular effects need to be further assessed to better understand the aetiology of PPP2R5D-related neurodevelopmental disorders.

Previous research has shown that PPP2R5B plays a role in neuronal development and function. For instance, B56β inhibits dendritic branching, through dephosphorylation of Akt in Akt-dependent dendritic branching (Brandt et al., 2008). However, gene knockouts of Ppp2r5b or Ppp2r5c were viable in mice, and showed no brain abnormalities (Verbinnen et al., 2021). Thus far, both PPP2R5B and PPP2R5C mutations have been found in one patient each, identified within a selected cohort of individuals exhibiting overgrowth (Loveday et al., 2015) (Figure 3C). Both these variants affect the same conserved acidic loop as mutated in PPP2R5D, which provides substrate recognition for B56β, and C subunit binding for B56γ (Cho and Xu, 2007; Saraf et al., 2010). Despite lack of biochemical characterisation, these variants are thought to act dominant-negative as well, mimicking the action of PPP2R5D variants. As such, further investigation of these variants is warranted to confirm this hypothesis. In addition, specific screening for these genes could increase the number of identified patients and potentially identify more variants.

Taken together, PP2A-related neurodevelopmental disorders are a diverse set of diseases, with multiple subunits of PP2A mutated, leading to a variety of symptoms. Despite this variety of affected subunits, remarkably similar phenotypes have been identified with common symptoms including intellectual disability, developmental delay, hypotonia, brain (size) abnormalities, and often, epilepsy and ASD. Despite being relatively well characterised molecularly, an exact cellular disease mechanism remains unknown, in terms of which neuronal substrates could be affected in their (de) phosphorylation. Thus, to fully understand these diseases, more research needs to be performed to pinpoint which molecular pathways are affected by variants in PP2A subunits. Due to the lowering costs of genomic sequencing tools, more patients are being identified worldwide, and additional variants are found that could help expand the current knowledge regarding molecular and biochemical properties of PP2A subunits.

3.1.2.2 Other congenital PP2A-related diseases

Apart from PP2A-related intellectual disabilities, some other congenital mutations have been found in PPP2R2B (OMIM#604326) and PPP2R3C (OMIM#618419) (Figure 3D). PPP2R2B, encoding the B55β subunit, was implicated as causative in spinocerebellar ataxia 12, with patients presenting with upper extremity tremor, progressing to head tremor, gait ataxia, dysmetria, dysdiadochokinesis, hyperreflexia, paucity of movement, and abnormal eye movements - eventually developing dementia. Patients were found to be carrying a number of expanded CAG repeats, 133 nucleotides upstream of the transcription start site of PPP2R2B (Holmes et al., 1999). The authors concluded that this CAG expansion might affect PPP2R2B expression, and is probably causative due to the lack of such expansion in controls, and the correlation between expansion degree and disease (Holmes et al., 1999); however, no expression or functional studies were performed to conclusively point out PPP2R2B as the cause of spinocerebellar ataxia 12, or to elucidate the mechanism through which this disease manifests itself.

Homozygous PPP2R3C mutations were found to cause 46, XY gonadal dysgenesis, with patients presenting with female external genitalia despite an XY karyotype, a hypoplastic
uterus, dysmorphic features, a common facial gestalt, myopathy and a thick muscular build, neuromotor delay, and intellectual disability (Guran et al., 2019) (OMIM#618419). \( \text{PPP2R3C} \), encodes the \( \text{Ca}^{2+} \)-regulated \( \text{B}''' \gamma / \text{G5PR} \) subunit and is relatively ubiquitously expressed (Janssens et al., 2003; Zwaenepoel et al., 2008). The only studies on the role of \( \text{PPP2R3C} \) focussed on the immune system: knockout studies in mice have shown an important role of \( \text{Ppp2r3c} \) in B- and T-cells, regulating their development and proliferation (Reynhout and Janssens, 2019). However, until the identification of these patients, \( \text{PPP2R3C} \) was unknown to play a role in human sex development.

Histology performed on digenetic gonads of patients revealed an absence of phospho-Sox9, a direct downstream target of PP2A indispensable for testicular development, thus indicating gain-of-function (Guran et al., 2019). Given the autosomal recessive inheritance of this disease, the authors also investigated the effect of heterozygous \( \text{PPP2R3C} \) variants on reproductive functions. They found that heterozygous fathers had teratozoospermia with severe head, acrosomal, and nuclear abnormalities. Heterozygous mothers reported oligomenorrhea and hypomenorrhea, or an unaffected menstrual cycle. Furthermore, B-lymphocyte viability was affected, with CD19+ B-lymphocytes from homozygous patients being more susceptible to apoptosis and proliferating less, compared to healthy controls (Guran et al., 2019). This study clearly links \( \text{PPP2R3C} \) mutations to gonadal dysgenesis, through a phospho-Sox9 deficiency, possibly by PP2A hyperactivity, but does not provide direct functional studies of the effect of these mutations on protein function and dephosphorylation. Thus, further functional studies, and possible other effects, apart from Sox9 dephosphorylation, are needed to fully characterise these variants.

### 3.1.3 Calcineurin

Calcineurin (or PP2B) forms a complex of one catalytic subunit (encoded by three possible genes: \( \text{PPP3CA}, \text{PPP3CB} \) and \( \text{PPP3CC} \)), one \( \text{Ca}^{2+} \)-binding regulatory subunit (\( \text{PPP3R1} \) or \( \text{PPP3R2} \)), and \( \text{Ca}^{2+} \)/calmodulin to release auto-inhibition (Roy and Cyert, 2020) (Figure 1B). Like PP1 and PP2A, PP2B achieves substrate specificity through binding to SLIMs, such as the PxIxIT and LxVP motifs, that are present in their substrates, regulators and anchoring proteins (Wigington et al., 2020). Of the five human PP3 genes, one is implicated in genetic disease: \( \text{PPP3CA} \) (OMIM#618265, #617711) (Myers et al., 2017; Mizuguchi et al., 2018), while \( \text{PPP3CC} \) is linked to schizophrenia susceptibility (Gerber et al., 2003). Calcineurin is the most abundant calmodulin-binding protein in adult brain, mostly expressed in the neuronal cell body and processes (Khan et al., 2021). In the brain, calcineurin plays a key role in memory, synaptic plasticity, and synaptic transmission through the regulation of several pre- and postsynaptic targets, mainly ion channels and neurotransmitter receptors (Purkey and Dell’Acqua, 2020; Khan et al., 2021). Embryonic neural induction has been shown to be dependent on calcineurin, regulating the bone morphogenic protein-regulated Smad1/5 proteins after fibroblast growth factor stimulation (Cho et al., 2014). Congenital disease caused by\( \text{PPP3CA} \) alterations can be attributed to gain-of-function mutations, or loss-of-function mutations, evidenced by activation or repression of downstream calcineurin signalling, respectively. To note, all relevant mutations were found to be heterozygous, and most to be de novo.
Mizuguchi et al. found several mutations, generally mapping to two distinct locations in the protein (Figure 4). One set of variants (p.His92Arg, p.Asn150Ile, and p.Asp234Glu) were found to affect the catalytic domain of PP2B α, leading to patients presenting with similar clinical features, such as non-syndromic epileptic encephalopathy with spasms and hypsarhythmia (Mizuguchi et al., 2018). One other variant, p.Met431Hisfs*20 led to a similar phenotype, thus likely acting in a similar fashion as the previous mutations. These mutants in the catalytic domain were found to be loss-of-function, as evidenced by measuring calcium sensitivity in a yeast model system lacking ppb1 (encoding a calcineurin catalytic subunit, CnA, in S. pombe), making them intolerable to high calcium growth conditions. In this model, overexpression of ppb1 with the conserved mutations in the catalytic domain failed to rescue this growth phenotype (Mizuguchi et al., 2018). Furthermore, two variants, p.Ala473Thr and p.Phe470Leu, were found to map to the auto-inhibitory domain of PP2B α, leading to different clinical features, such as intellectual disability, craniosynostosis, cleft palate, micrognatia, arthrogryposis and short stature (Mizuguchi et al., 2018). However, facial dysmorphism varied among patients. Using the same yeast model system, these mutations were shown to be gain-of-function, evidenced by their enhanced ability to rescue calcium intolerance as compared to wild-type ppb1. Additionally, both sets of mutants were tested for their ability to activate a downstream transcription factor Prz1, which confirmed the previously determined loss-of-function and gain-of-function mechanisms of these variants (Mizuguchi et al., 2018).

An earlier study identified six PPP3CA variants, p.His92Arg, p.Arg254Gly, p.Gln281Gln, p.Glu282Lys, p.Gln445*, and p.Ala447Thr, but no functional studies were performed (Figure 4) (Myers et al., 2017). Four of these substitutions affected the catalytic domain, i.e. His92Arg (as previously discussed), and Arg254Gly, His281Gln and Glu282Lys (Myers et al., 2017), while the other two variants seemed to reside close to the auto-inhibitory domain (Figure 4). All patients presented with profound to severe intellectual disability, developmental delay, and five out of six patients had epilepsy. These authors did not make a distinction between the two different sets of mutations, nor between phenotypes based on these mutations. As such, it would be interesting to re-evaluate the functional impact of these mutations using the same techniques Mizuguchi et al. had used, to see if their breakdown of the phenotype holds true in these patients as well. Furthermore, such assays could be used to further confirm their general conclusion that mutations in the catalytic domain led to a loss-of-function, while mutations in the auto-inhibitory domain led to gain-of-function, which explained the two separate phenotypes they noted in their 2018 study.

Several independent studies performed linkage analysis where they identified PPP3CC as a susceptibility locus for schizophrenia (Gerber et al., 2003). Further investigation showed that this susceptibility was conferred through a single point mutation, a substitution of amino acid 163, changing a positively charged arginine to a neutral glutamine (Figure 4) (Gerber et al., 2003). Furthermore, this study confirmed expression of PPP3CC in both adult and foetal brain tissue (Gerber et al., 2003). Despite strong genetic evidence, no causal relations have been found, and no functional studies have been performed to identify the exact mechanism of this susceptibility, or if neighbouring genes are the cause of this susceptibility.

3.2 PPMs

3.2.1 PP2C family

Of the thirteen members of the PP2C family, four are linked to congenital disease: PPM1B, PPM1D (OMIM#167450), PPM1F, and PPM1K (OMIM#615135). PPM1B is one of the genes lost in the homozygous 2p21 deletion syndrome (Parvari et al., 2001, 2005; Jaeken et al., 2006), while mutations in PPM1D cause Jansen-de Vries syndrome (Jansen et al., 2017). Furthermore, PPM1F is a variant of unknown significance in familial intrahepatic cholestasis (Maddirevula et al., 2019), and PPM1K has a homozygous association with maple syrup urine disease (Oyarzabal et al., 2013).

PP2CB protein (encoded by PPM1B) is highly expressed in adult brain and gastrointestinal tissue, while PPM1B RNA is found in high quantities in muscle tissue (Uhlén et al., 2015; Karlsson et al., 2021). PP2CB is implicated in regulating necroptosis, senescence, adipogenesis, antiviral response, and the cell cycle (Kamada et al., 2020). Interestingly, Ppm1b deletion in mice has been reported to lead to embryonic lethality, with mRNA expression in wild-type mice being high at sperm maturation and in cell cycle arrested oocytes, while expression decreased between the two- and eight-cell stage of the embryo. Thus, PP2CB seems to play an important role in both early embryonic development and adult brain function (Kamada et al., 2020). Interestingly, Ppm1b is fully lost in patients with homozygous 2p21 deletion syndrome, where 179,311 bp of DNA of chromosome 2p21 are deleted (Figure 5) (Parvari et al., 2001, 2005). Apart from PPM1B, three other genes are affected: the full type 1 cystinuria gene SLC3A1, the full, mostly uncharacterised, serine peptidase-encoding gene PREPL, and the first exon of the class I protein methyltransferase gene C2orf54. Patients present with cystinuria, neonatal seizures, hypotonia, severe somatic and developmental delay, facial dysmorphisms, and lactic acidemia. Researchers concluded that the cystinuria can be attributed to the heterozygous loss of SLC3A1; however, the exact role of the other affected genes has remained unclear in the development of the phenotype (Parvari et al., 2001, 2005). A further study of new
families presenting with cystinuria-hypotonia found that in some patients only SLC3A1 and PREPL were deleted, while PPM1B and C2orf34 remained unaffected. Thus, researchers concluded that SLC3A1 causes cystinuria, while PREPL likely causes the remaining phenotypic features. Consequently, the exact role of PPM1B in this disease remains unstudied, but is hypothesised to be minimal (Jaeken et al., 2006).

PP2Cδ or WIP1 (Wild-type p53 induced protein phosphatase 1), encoded by PPM1D, is a well-studied phosphatase, implicated in several processes, such as cell cycle regulation, metabolism, immune cell development and immune response, spermatogenesis, autophagy, and in cancer, it was established as an oncogene (Emelyanov and Bulavin, 2015; Kamada et al., 2020). PPM1D RNA is highly expressed in adult brain, while protein levels can be found in high quantities in brain, endocrine tissues, gastrointestinal tract, liver and gallbladder, kidney, male genitalia, and bone marrow and lymphoid tissues (Kamada et al., 2020). Furthermore, WIP1 is essential for adult neurogenesis through regulation of neural stem/progenitor cell differentiation. Researchers found that Wnt signalling is inhibited in aged neural stem/progenitor cells, barring them from differentiation, due to a lower expression of PPM1D. By stimulating Wnt signalling, neurogenesis was rescued in aged cells, and the authors proposed modulation of WIP1 can lead to the same effect (Zhu et al., 2014).

Given the high expression and important role of PPM1D in brain tissue, it came as no surprise that mutations in PPM1D can cause disease related to brain development. De novo, heterozygous mutations in PPM1D have indeed been identified as the cause of Jansen–de Vries syndrome, with patients presenting with mild to severe intellectual disability and/or developmental delay, autism spectrum disorder, ADHD, anxiety disorders, hypotonia, broad-based gait, facial dysmorphisms, and periods of fever and vomiting (Jansen et al., 2017). All identified mutations in PPM1D appeared nonsense or frameshift mutations, and are located in the last or next-to-last exon, thus leading to an escape of nonsense-mediated decay and normal expression of the protein (Figure 5). However, all variants of PPM1D lack the nuclear localisation signal (NLS), probably barring the protein from entering the nucleus, while the wild-type protein still does. WIP1 plays an important role in cellular stress, notably in the p53 pathway following DNA damage (Fiscella et al., 1997), where it regulates the phosphorylation state of CHK1 (Checkpoint kinase 1) and p53 itself (Lu et al., 2005). Furthermore, WIP1 regulates p38 MAPK signalling, creating a feedback loop with p53, since PPM1D is induced by p53 (Choi et al., 2002). Thus, it is of no surprise that somatic PPM1D gain-of-function mutations have also been implicated in cancer, including breast and colon cancer (Emelyanov and Bulavin, 2015). Interestingly, in Jansen–de Vries syndrome, the cellular stress pathway induced by ionizing radiation seems unaffected by mutations in PPM1D, possibly due to the presence of the wild-type allele. However, cells derived from patients showed a growth disadvantage when compared to...
control cells (Jansen et al., 2017). Furthermore, **PPM1D** was found to be widely expressed in foetal organs, such as liver, skeletal tissue, and brain, suggesting an important role in foetal development. Large database queries showed that **PPM1D** is under constraint for missense mutations, while it seems tolerant for loss-of-function mutations. Thus, it is hypothesised that pathophysiological mechanisms underlying ID-associated **PPM1D** mutations are complex in origin, with a C-terminally truncated protein probably being more disruptive than full loss of the protein, in line with a dominant-negative disease mechanism (Jansen et al., 2017). Here as well, no functional phosphatase activity assays were performed, which could shed more light on the exact mechanism through which C-terminally truncated **WIP1** variants causes Jansen–de Vries syndrome.

**PPM1F** is ubiquitously expressed in human tissue and has been shown to play a role in regulating the kinesin motor complex, **mDia1-** and **RhoA-**dependent transcription mediated by serum response factor, neurofilament L function, oxidative stress response, depression, anxiety, cancer, Alzheimer’s disease, diabetes and inactivation of **Ca**²⁺/calmodulin-dependent protein kinase II (**CAMKII**) - hence its frequently used protein name, **CAMK** phosphatase (Kamada et al., 2020). Furthermore, **PPM1F** has been implicated to play a role in familial intrahepatic cholestasis, where one affected, consanguineous, family was identified (Maddirevula et al., 2019). One sibling presented with fatal liver failure at age 13, while another sibling presented with neonatal low gamma-GT cholestasis and jaundice, and indications of sclerosing cholangitis at age 19. At age 21, the patient suffered from short stature, portal hypertension, hypothroidism, and a hyperpigmented tongue. This family was identified to carry a homozygous **PPM1F** variant, p.Arg302Cys (Figure 5). Interestingly, in the same study the authors identified a family with similar symptoms, but with mutations in a different gene, **KIF12**. As both **KIF12** and **PPM1F** play a role in centrosome orientation and kinesin-mediated transport, the authors hypothesised this disease as a cholangiocloptopyth caused by primary cilia dysfunction (Maddirevula et al., 2019). Important to note is that **PPM1F** mutations have only been found in one family, and no functional studies have been performed on the exact effect of this mutation on phosphatase binding and function.

Expression of **PPM1K**, encoding **PP2Cκ**, is highest in heart and brain but is otherwise ubiquitous (Uhlén et al., 2015; Karlsson et al., 2021). Within cells, **PP2Cκ** localises to the mitochondria where it regulates mitochondrial permeability, making it indispensable for cell survival and development, and cardiac function (Kamada et al., 2020). Furthermore, **PP2Cκ** regulates the degradation of the branched-chain α-keto acid dehydrogenase complex, and the stemness of hematopoietic stem cells (Kamada et al., 2020). As the sole regulator of the branched-chain α-keto acid dehydrogenase complex, **PP2Cκ** has been implicated in a mild variant phenotype of maple syrup urine disease. A homozygous deletion of base pairs 217T and 218A in the **PPM1K** cDNA has indeed been found to be causally linked to this disease. This 2-bp-deletion creates a C-terminally truncated protein through a frameshift, leading to a premature stop codon after Thr140 (Oyarzabal et al., 2013) (Figure 5). Maple syrup urine disease is caused by accumulation of valine, leucine, isoleucine, and their respective branched-chain α-keto acids, in cells and body fluids through a deficient activity of the branched-chain α-keto acid dehydrogenase. This accumulation leads to a range of mild to severe clinical phenotypes, including ketoacidosis, ataxia and neurological symptoms, due to the accumulation of these neurotoxic metabolites. **PPM1K** is the only known phosphatase regulator of the phosphorylation state of branched-chain α-keto acid dehydrogenase, where association between **PP2Cκ** with branched-chain α-keto acid dehydrogenase leads to activation of the complex (Zhou et al., 2012). Researchers performed functional studies in fibroblasts derived from patients, which contain the p.Thr140fs* variant, and found a decrease in function of branched-chain α-keto acid dehydrogenase, which was rescued by expression of wild-type **PPM1K** (Oyarzabal et al., 2013). Additionally, reactive oxygen species were found in higher concentrations in cells lacking functional **PPM1K**, and JNK and p38 kinases were induced. However, no change was observed in cell cycle progression. These experiments provided conclusive proof that a loss-of-function variant in **PPM1K** causes a mild phenotype of maple syrup urine disease and is a prime example of the direct effect of genetic variation in a Ser/Thr phosphatase gene on normal cell function (Oyarzabal et al., 2013).

### 3.2.2 PHLPP and PDP

Of the four remaining PPM phosphatases, **PHLPP1, PHLPP2, PDP1**, and **PDP2**, only **PDP1** is thus far implicated in congenital disease (OMIM#608782). As one of two possible catalytic subunits of pyruvate dehydrogenase phosphatase, **PDP1** is predominantly expressed in skeletal muscle, while **PDP2** is more abundant in liver. **PDP1** localises to the mitochondrial matrix, where it catalyses the dephosphorylation of pyruvate dehydrogenase, thus activating it (Lawson et al., 1993; Maj et al., 2006). Variants in **PDP1** can cause pyruvate dehydrogenase complex deficiency, a heterogeneous mitochondrial disorder with varying phenotypes, such as fatal infantile lactic acidosis, chronic neurological dysfunction, and intermittent ataxia (Maj et al., 2006; Cameron et al., 2009; Bedoyan et al., 2019). So far, three homozygous mutations that cause pyruvate dehydrogenase complex deficiency have been identified in **PDP1**: a 3-bp-deletion leading to deletion of leucine 213, a G-T transversion leading to a premature stop codon at amino acid 93, and a 1-bp-duplication at base pair 575, leading to a premature stop codon at amino acid 192 (Figure 5). Of all mutants, patient-derived fibroblasts were cultured, and activity of pyruvate dehydrogenase complexes measured, showing a decrease in activity of all three variants (Maj et al., 2006; Cameron et al., 2009; Bedoyan et al., 2019). This led to the conclusion that variants in **PDP1** are loss-of-function
and cause a decrease in pyruvate dehydrogenase complex activity, thus contributing to disease. To note is that none of the three studies performed specific phosphatase activity assays of the variants to fully elucidate the exact molecular effect of these variants on PDP1 action.

3.3 HADs

Of the seven genes encoding HAD monomeric phosphatases (CTDP1, CTDSP1, CTDSP2, CTDSP1L, CTDSP2L, CTDNEP1, and UBLCP1) only the first one is currently known to cause an inborn genetic disease (OMIM#604168) (Varon et al., 2003). CTDP1 encodes FCP1, a phosphatase that dephosphorylates serine 2 and serine 5 in the Tyr-Ser-Pro-Thr-Ser-Pro-Ser repeats at the C-terminal domain of RNA polymerase II, thus activating transcription initiation (Seifried et al., 2013), and is relatively ubiquitously expressed (Uhlén et al., 2015; Karlsson et al., 2021). A single point mutation in CTDP1 was identified as the cause of a diverse phenotype in the Vlax Roma population, including congenital cataracts, facial dysmorphisms, and neuropathy, referred to as CCFDN (Congenital Cataracts, Facial Dysmorphism, and Neuropathy) syndrome (Varon et al., 2003). CCFDN syndrome is caused by a single, homozygous point mutation in an intronic, antisense Alu element between exons 6 and 7 of CTDP1, substituting a C for a T. This substitution leads to the creation of a donor splice site 389 bp downstream the end of exon 6 of CTDP1 (Figure 6). Thus, the mutation creates the opportunity for alternative, aberrant splicing, where 95 nucleotides belonging to the antisense Alu sequence are inserted in the processed CTDP1 mRNA. Due to this insertion, a frame shift of the reading frame occurs, leading to a premature termination signal, 17 codons downstream of the end of exon 6. Following this premature termination signal, it is hypothesised that the subsequent variant of FCP1 will be either non-functional or undergo nonsense-mediated decay (Varon et al., 2003). Interestingly, the wild-type transcript was still present in the affected patient, showing that both normal and aberrant splicing occur, causing a partial deficiency. Further investigation is warranted to conclusively confirm if the disease-causing variant of FCP1 indeed does undergo nonsense-mediated decay, or if, when not decayed, it loses functionality.

4 Conclusions and future perspectives

Given the lowering costs of exome and genome sequencing, it should be of no surprise that more genetic diseases have been identified during the last decade than at any time before. In particular, the notion that a small number of de novo mutations occurring during gametogenesis or post-zygotically, can become a major cause of developmental disorders (Veltman and Brunner, 2012; de Ligt et al., 2013), has not only resulted in providing final, sometimes long-sought after, diagnoses to many patients and families, but has also provided novel research opportunities to better understand the normal and diseased function of proteins.

Until recently, and unlike protein kinases, mutations in serine/threonine protein phosphatases (PSP) were not commonly associated with disorders of human development. Overall, of 38 human genes encoding PSP catalytic subunits or monomeric phosphatases, 10 were found to be affected in congenital disorders or were associated with an increased disease predisposition: PPP1CB, PPP2CA, PPP3CA, PPP3CC, PPP1MB, PPP1D, PPP1F, PPP1K, PDP1 and CTDP1, thus representing members of all three PSP subfamilies. In addition, 9 genes encoding a regulatory subunit of one of the multimeric PSP phosphatases were also among the congenital disease genes: PPP1R12A, PPP1R15B and PPP1R21, encoding regulatory subunits of PP1, and PPP2R1A, PPP2R2C, PPP2R5B, PPP2R5C, PPP2R5D and PPP2R3C, encoding subunits of PP2A.

In most cases, PSP gene mutations caused losses-of-function of the associated gene products, with just a few examples of gain-of-function.
of-function variants (in PPP1CB, PPP3CA (some) and PPP2R3C). This observation has important ramifications for potential therapeutic interventions, as in general, it is more difficult to restore damaged phosphatase activity or expression by pharmacologic modulators, than to inhibit uncontrolled phosphatase activity or to interfere with increased phosphatase-substrate binding. In the former cases, alternative targeting of the relevant PSP downstream targets, e.g. by interfering with the upstream protein kinase activities, remains an appealing option to compensate for the loss of PSP activities. However, this necessitates knowledge about the affected physiologic substrates of the phosphatase, dysphosphorylation of which is causally involved in certain disease symptoms, as well as knowledge about the identity of the upstream kinase(s), and these insights are still often lacking.

On the other hand, several PSP phosphatase activating pharmacopeptide mimics did recently emerge (Wang et al., 2010; De Munter et al., 2013; Hasbbeck et al., 2015; Brautigan et al., 2021), although their precise mechanisms-of-action often remain unclear or are under debate (Vit et al., 2022), and it seems unlikely that these compounds will be able to restore the function of genetically inactivated phosphatase gene products. In contrast, it has been known for a long time that potent pharmacologic PPP inhibition can be achieved by several naturally occurring toxins, such as calyculin A or microcystin-LR (Swingle et al., 2007; Zhang et al., 2013), while many PPM and HAD phosphatase inhibitors were identified through chemical compound library screening (Rogers et al., 2006; Siercke et al., 2010; Zhang et al., 2013; Pecháčková et al., 2017). However, all these inhibitors target the highly conserved catalytic site of PSP phosphatases and are thus not very selective. Hence, it would be interesting to further explore the possibilities of finding pharmacological inhibitors that specifically target PPP holoenzymes, the non-catalytic domains of monomeric PPP phosphatases, or PSP enzyme-substrate complexes (Gilmartin et al., 2014; Krzyzosiak et al., 2018) to increase their specificity and avoid the undesirable pleiotropic actions (side effects) of catalytic site-targeted PSP inhibitors. Alternatively, novel gene therapy approaches, using improved CRISPR or RNA interference technology, and aiming to selectively edit or downregulate the mutation at DNA or mRNA level, remain valuable surrogates to pharmacologic interventions.

In general, the functional impact of identified mutations is easier to understand and to investigate in the monomeric PSP phosphatases, while this can be much more complex in the multimeric phosphatases, especially if mutations affect the common catalytic C-subunit (or, as is the case for PP2A, the common scaffolding A-subunit), and thus may have different effects on different holoenzyme complexes. For example, extensive molecular characterisation of PPP2CA and PPP2R1A variants has revealed an unexpectedly high complexity of holoenzyme assembly defects that are still incompletely understood, especially at the functional level, but that certainly could explain the opposite clinical features observed in some affected cases (e.g., macro- vs. microcephaly). Moreover, it brings up the provocative question how different variants within a single affected PP2A gene, and variants in different PP2A genes may, or may not, relate to each other and affect similar pathways, potentially resulting in common, or different, molecular and/or clinical subgroups. The latter may have, again, important consequences for therapeutic intervention strategies.

Remarkably, in this overview of PSP congenital disorders, we often have encountered phenotypes that are specifically associated with brain dysfunction or dysmorphology, despite mutations being omnipresent in the human body, and the widespread tissue expression of most PSP genes. Thus, we must conclude that PSP-dependent protein dephosphorylation has a major potential for regulation of brain development and function. Nevertheless, some PSP disorders manifested themselves in other organs too, including the (uro)genital and endocrine systems, and were, in these cases, often linked to alterations in specific molecular pathways.

Thus far, few biochemical and molecular studies have been performed to investigate the effect of mutations on PSP protein function, downstream targets and associated pathways. Probably, the best-studied diseases in these respects are those involving mutations in PPP1CB, PPP1R15B, PPM1K and PDP1, followed by the PPP2- and PPP3CA-related neurodevelopmental disorders. Even in these relatively better understood diseases, knowledge is still incomplete, and in particular, the further identification of downstream targets and effectors could elucidate the exact mechanisms through which these diseases act, and possibly open up therapeutic avenues. To this end, new emerging technologies to identify PSP phosphatase substrates have been proposed that could be of value (Fahs et al., 2016), but there is still a long way to go, as the complexity is major. Of primary importance to achieve these goals, seems the generation and comprehensive characterisation of appropriate in vitro and in vivo disease models, such as appropriate knockout or knockin mice, and patient-derived cell models, including induced pluripotent stem cells that can be re-differentiated into the appropriate cell types. Finally, the number of diagnoses and of new variants affecting PSP genes is likely still to increase further in the near future, which may also help to identify new PSP functional domains and regulation mechanisms that could be of relevance to help decipher their physiologic functions.

In conclusion, PSP genes are obviously new players in congenital developmental disorders, mainly affecting the brain. On the longer term, this opens up new opportunities for clinical intervention, although much more research is required on the shorter term to understand through which
mechanism(s) these gene variants cause the associated clinical phenotypes.

Author contributions

PV wrote the manuscript and designed figures, IV revised the manuscript, and VJ wrote and revised the manuscript.

Acknowledgments

We thank the following funding agencies for their support: the Marguerite-Marie Delacroix Foundation (to PV), the Research Foundation-Flanders (FWO-Vlaanderen) (to IV), and the Jordan’s Guardian Angels Foundation (to VJ).

References

Abdulkarim, B., Nicolino, M., Igloilo-Esteve, M., Daures, M., Romero, S., Philipp, A., et al. (2015). A missense mutation in PPP1R15B causes a syndrome including diabetes, short stature, and microcephaly. Diabetes 64 (11), 3951–3962. doi: 10.2337/db15-0477

Ahn, J. H., McCay, T., Rakhlin, S. V., Nishi, A., Greengard, P., and Nairn, A. C. (2007). Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56delta subunit. Proc. Natl. Acad. Sci. U. S. A. 104 (8), 2979–2984. doi: 10.1073/pnas.0611532104

Alkhunaizi, E., and Chitayat, D. (2021). “PPP1R12A-Related urogenital and/or brain malformation syndrome,” in GeneReviews® [Internet]. Editors M. P. Adam, D. B. van Driessche, A. E. Beaudet, A. R. Pagon, S. E. Wallace, L. J. H. Bean, et al. (Seattle WA: University of Washington, Seattle)-2021.

Backx, L., Vermeesch, J., Pijls, E., de Ravel, T., Seuntjens, E., and Van Esch, H. (2010). PPP2R2C, a gene disrupted in autosomal dominant ichthyosis, associated with congenital heart defects. Eur. J. Med. Genet. 53 (5), 239–243. doi: 10.1016/j.ejmg.2010.06.006

Baff, T. R., Katsnelson, K. C., and Newton, A. C. (2021). PHLPping the script: Emerging roles of PHLP phosphatases in cell signaling. Annu. Rev. Pharmacol. Toxicol. 61, 723–743. doi: 10.1146/annurev-pharmaco-031820-122108

Baker, E. K., Solivio, B., Pode-Shakked, B., Cross, L. A., Sullivan, B., Raas-Rothschuld, A., et al. (2022). PPP2R1A neurodevelopmental disorder is associated with congenital heart defects. Am. J. Med. Genet. A. 183 (3), 824–828. doi: 10.1002/ajmg.a.39070

Bedoyan, J. K., Hecht, L., Zhang, S., Tarrant, S., Bergin, A., Demirbas, D., et al. (2019). A novel null mutation in the pyruvate dehydrogenase phosphatase catalytic subunit gene (PDP1) causing pyruvate dehydrogenase complex deficiency. JIMD Rep. 48 (1), 26–35. doi: 10.1007/s00439-012-0205-4

Bertola, D., Yamamoto, G., Buscarilli, M., Jorge, A., Passos-Bueno, M. R., and Kim, C. (2017). The recurrent PPP1R1C mutation p.Pro49Arg in an additional Noonan-like syndrome individual: Broadening the clinical phenotype. Am. J. Med. Genet. A 173 (3), 824–828. doi: 10.1002/ajmg.a.38190

Bisson-Lauber, A., Lang-Murriano, T., Vaccaro, T., and Schoenle, E. J. (2002). Loss of kinase activity in a patient with Wolcott-Rallison syndrome caused by a novel mutation in the EIF2AK3 gene. Diabetes 51 (7), 2301–2305. doi: 10.2337/diabetes.51.7.2301

Buiwaw, D., Cary, W., and Nolta, J. A. (2020). PPP2R3D-related intellectual disability and neurodevelopmental delay: A review of the current understanding of the genetics and biochemical basis of the disorder. Int. J. Mol. Sci. 21 (4), 1286. doi: 10.3390/ijms21041286

Brandt, N., Franke, K., Johannes, S., Buck, J., Harder, S., Hassel, B., et al. (2008). Bifbeta, a regulatory subunit of protein phosphatase 2A, interacts with CALEB/NGC and inhibits CALEB/NGC-mediated dendritic branching. FASEB J. 22 (7), 2521–2533. doi: 10.1096/fj.07-096115

Brautigan, D. L., Farrington, C., and Narla, G. (2021). Targeting protein phosphatase 2A for cancer therapy: Development of allosteric pharmaceutical agents. Clin. Sci. 135 (13), 1545–1556. doi: 10.1042/CS202101367

Brautigan, D. L. (2013). Protein Ser/Thr phosphatases—the ugly ducklings of cell signaling. FEBS J. 280 (2), 324–345. doi: 10.1111/1742-4658.2012.08669.x

Cameron, J. M., MajM.Levandovský, V., Barnett, C. P., Blaér, S., MackayN, et al. (2009). Pyruvate dehydrogenase phosphatase 1 (PDP1) null mutation produces a lethal infantile phenotype. Hum. Genet. 125 (3), 319–326. doi: 10.1007/s00439-009-0629-6

Campos, A., and Clemente-Blanco, A. (2020). Cell cycle and DNA repair regulation in the damage response: Protein phosphatases take over the reins. Int. J. Mol. Sci. 21 (2), 46. doi: 10.3390/ijms21020446

Cho, A., Tang, Y., Davila, J., Deng, S., Chen, L., Miller, E., et al. (2014). Calcineurin signaling regulates neural induction through antagonizing the BMP pathway. Neuron 82 (1), 109–124. doi: 10.1016/j.neuron.2014.02.015

Cho, U. S., and Xu, W. (2007). Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 445 (7123), 53–57. doi: 10.1038/nature05351

Choi, J., Nannenga, B., Demidov, O. N., Bulavin, D. V., Cooney, A., Bratyon, C., et al. (2002). Mice deficient for the Wild-Type p53-Induced Phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol. Cell. Biol. 22 (4), 1984–1995. doi: 10.1128/mcb.22.4.1984-1995.2002

Cohen, P. T. W. (1997). Novel protein serine/threonine phosphatases: Variety is the spice of life. Trends biochem. Sci. 22 (7), 245–251. doi: 10.1016/S0968-0009(97)01060-8

Connor, J. H., Weiser, D. C., Li, S., Hallenbeck, J. M., and Shenolikar, S. (2001). Growth arrest and DNA damage-inducible protein GADD45 assembles a novel signaling complex containing protein phosphatase 1 and inhibitor 1. Mol. Cell. Biol. 21 (20), 6841–6850. doi: 10.1128/MCB.21.20.6841-6850.2001

Cundell, M. J., Hutter, L. H., Nunes Bastos, R., Poser, E., Holder, J., Mohammed, S., et al. (2016). A PP2A-B55 recognition signal controls substrate dephosphorylation kinetics during mitotic exit. J. Cell Biol. 214 (5), 539–554. doi: 10.1083/jcb.201606033

de Ligt, J., Veltman, J. A., and Vissers, L. E. L. M. (2013). Point mutations as a source of de novo genetic disease. Curr. Opin. Genet. Dev. 23 (3), 257–263. doi: 10.1016/j.gde.2013.01.007

De Munter, S., Kohn, M., and Bollen, M. (2013). Challenges and opportunities in the development of protein phosphatase-directed therapeutics. ACS Chem. Biol. 8 (1), 36–45. doi: 10.1021/cb300597g

Deciphering Developmental Disorders Study (2015). Large-scale discovery of novel genetic causes of developmental disorders. Nature 519 (7542), 223–228. doi: 10.1038/NATURE14135

Delépine, M., NicolinoM.BarrettTT, T., GolaMaudlyM.Lathrop, G. M., and Julier, C. (2000). EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat. Genet. 25 (4), 406–409. doi: 10.1038/787085

Delibegovic, M., Armstrong, C. G., Dobbie, L., Watt, P. W., Smith, A. J. H., and Cohen, P. T. W. (2003). Disruption of the striated muscle glycogen targeting protein kinase A. Proc. Natl. Acad. Sci. U. S. A. 100 (13), 743–748. doi: 10.1073/pnas.1331280100

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
subunit PPP1R3A of protein phosphatase 1 leads to increased weight gain, fat deposition, and development of insulin resistance. *Diabetes* 52 (3), 596–604. doi:10.2337/diabetes.52.3.596

Dourou, S., Janssens, V., and Foubert, B. (2022) in PPP2R5D-Related neurodevelopmental disorder. GeneReviews® [Internet]. Editor: M. P.Adam, D. B. Everman, G. M. Mirzaa, R. A. Pagon, S. E. Wallace, L. J. H. Bean, et al. (Seattle, WA): University of Washington, Seattle), 1993–2022.

Dyson, J. J., Abbasi, F., Varzadkar, P., and McCright, B. (2022). Growth arrest of PP1B/PPP2B double knockout mice indicates a genetic interaction and conserved function for these PPP2B subunits. FEBS Biochem. 4 (4), 273–282. doi:10.1093/febbio.2021-00130

Emelenyov, A., and Bulavin, D. V. (2015). Wip1 phosphatase in breast cancer. Oncogene 34 (34), 4429–4438. doi:10.1038/onc.2014.375

Fahs, S., Lujan, P., and Kohn, M. (2016). Approaches to study phosphatases. ACS Chem. Biol. 11 (11), 2944–2961. doi:10.1021/acschembio.6b00570

Ferreira, M., Beullens, M., Bollen, V. M., and Van Eynde, E. (2019). Functions and therapeutic potential of protein phosphatase 1: Insights from mouse genetics. Biochem. Biophys. Acta. Mol. Cell Res. 1866 (1), 16–30. doi:10.1016/j.bbamer.2018.07.019

Fiscella, M., Zhang, H., Fan, S., SaKaguchi, K., Shen, S., Mercer, W. E., et al. (1997). Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc. Natl. Acad. Sci. U. S. A. 94 (12), 6804–6805. doi:10.1073/pnas.94.12.6048

Foley, K., McKee, C., Nairn, A. C., and Xia, H. (2021). Regulation of synaptic transmission and plasticity by protein phosphatase 1. J. Neurosci. 41 (44), 3040–3050. doi:10.1523/JNEUROSCI.0326-20.2021

Fowle, I., Zhao, Z., Xu, Q., Wasserman, J. S., Wang, X., Adeyemi, M., et al. (2021). PPP2B/PSa substrate recruitment as defined by the retinoblastoma-like protein p107. Elife 10, e63181. doi:10.7554/Elife.63181

Gerber, D. J., Hall, D., Miyakawa, T., Demars, S., Gogos, J. A., Karayioroglu, M., et al. (2003). Evidence for association of schizophrenia with genetic variation in the 8q21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc. Natl. Acad. Sci. U. S. A. 100 (15), 8993–8998. doi:10.1073/pnas.1432927100

Gilissen, C., Hehir-Kwa, J. Y., Thung, D. T., van de Vorst, M., van Bon, B. W. M., Fahs, S., Lujan, P., and Kohn, M. (2016). Approaches to study phosphatases. FASEB J. 30 (1), 36–55. doi:10.1096/fj.201501176

Golden, T., Swingle, M., and Honkanen, R. E. (2008). The role of serine/threonine protein phosphatase type 5 (PPP5) in the regulation of stress-induced signaling networks and cancer. *Mol. Cell. 35* (3), 417–439. doi:10.1016/j.molcel.2016.06.024

Kapfl, D., Gerber, K. H., Hopf, F. W., Seif, T., Khazraji, V., Bonci, A., et al. (2016). Protein phosphatase 2A and glycogen synthase kinase 3 signaling modulate prepulse inhibition of the acoustic startle response by altering cortical M-Type potassium channel activity. J. Neurosci. 30 (26), 8830–8840. doi:10.1523/JNEUROSCI.0097-10.2010

Karnada, R., Kudoh, F., Ito, S., Tani, I., Janairo, J. B. I., Osinczinski, J. G., et al. (2020). Metal-dependent ser/thr protein phosphatase PPM family: Evolution, structures, diseases and inhibitors. Pharmacol. Ther. 215, 107622. doi:10.1016/j.pharmthera.2020.107622

Kim, C. Y., Wirth, T., Hubsch, C., Nemeth, A. H., Okur, V., Anheim, M., et al. (2016). Early-onset parkinsonism is a manifestation of the PPP2R5D p.E200K mutation. *Fronts. Neurol.* 7, 243. doi:10.3389/fneur.2016.00243

Kim, C. Y., Wirth, T., Hubsch, C., Nemeth, A. H., Okur, V., Anheim, M., et al. (2016). Early-onset parkinsonism is a manifestation of the PPP2R5D p.E200K mutation. *Fronts. Neurol.* 7, 243. doi:10.3389/fneur.2016.00243
PPP3CA cause two distinct disorders.

Ekhlevitch, N., et al. (2018). Loss-of-function and gain-of-function mutations in Bpp2r1a. Biol. Open 7, 762–764. doi:10.1242/bio.023300

Liu, B., Sun, L. H., Huang, Y. F., Guo, L. J., and Luo, L. S. (2018). Protein phosphatase 2Aca gene knock-out results in cortical atrophy through activating hippo cascade in neuronal progenitor cells. Int. J. Biochem. Cell Biol. 95, 53–62. doi:10.1016/j.biocel.2017.12.015

Loddo, S., Alivi, V., Rado, F. C., Genovese, S. di Tommaso, S., Calverti, G., et al. (2020). PPP2R1A-related syndromic intellectual disability: Report of an adult patient and review. Am. J. Med. Genet. A 182 (12), 3014–3022. doi:10.1002/ajmg.a.61889

Vaneynde et al. 10.3389/fcell.2022.1030119

Oyama, N., Vaneynde, P., Reynhout, S., Pao, E. C., Timms, A., Fan, X., et al. (2022). The clinical, neuroimaging and molecular characteristics of PPP2R5D related neurodevelopmental disorders: An expanded series with functional characterization and genotype-phenotype analysis. J. Med. Genet. doi:10.1136/jmedgenet-2022-108713

Papke, C. M., Smolen, K. A., Swingle, M. R., Cressy, L., Heng, R. A., Toporians, M., et al. (2021). A disorder-related variant (E420K) of a PPP2A-regulatory subunit (PPP2R5D) causes constitutively active AKT-mTOR signaling and coordinated cell growth. J. Biol. Chem. 296, 100313. doi:10.1074/jbc.f2b.2021.100313

Park, I., and Lee, D. H. (2020). Functional roles of protein phosphatase 4 in multiple aspects of cellular physiology: A friend and a foe. BMB Rep. 53, 181–190. doi:10.5483/BMRRep.2020.53.4.019

Parvizi, R., Brodyansky, I., Elpeleg, O., MoSeS, L., DanDau, D., and Hershkovitz, E. (2001). A recessive contiguous gene deletion of chromosome 2p16 associated with cystinuria and a mitochondrial disease. Am. J. Hum. Genet. 69 (4), 869–875. doi:10.1086/323624

Rehnman, A. U., Naja, M., Kambouris, M., Al-Gazali, L., Makrythanasi, P., Rad, A., et al. (2019). Biallelic loss of function variants in PPP1R21 cause a neurodevelopmental syndrome with impaired endocytic function. Hum. Mol. Genet. 40 (3), 267–280. doi:10.1093/hmg/ddz182

Remmerrie, M., and Janssens, V. (2019). PPP2CA: A promising biomarker and therapeutic target in endometrial cancer. Front. Oncol. 9, 462. doi:10.3389/fonc.2019.00462

Reynhout, S., Janssen, S., Haesen, D., van Belle, S., de Munnik, S. A., Bongers, E. M., et al. (2019). De novo mutations affecting the catalytic Cα subunit of PP2A, PPP2R5CA, cause syndromic intellectual disability resembling other PPP2A-related neurodevelopmental disorders. Am. J. Hum. Genet. 104 (1), 139–156. doi:10.1016/j.ajhg.2018.12.002

Roy, J., and Cyert, M. S. (2020). Identifying new substrates and functions for an old enzyme: Calcineurin. Cold Spring Harb. Perspect. Biol. 12 (3), a035146. doi:10.1101/cshperspect.a035146

Sandul, P., Jeng, C. J., Merrill, R. A., Song, J., and Strack, S. (2021). Protein phosphatase 2A – structure, function and role in neurodevelopmental disorders. J. Cell Sci. 134 (13), jcs248187. doi:10.1242/jcs.248187

Saraf, A., Oberg, E. A., and Strack, S. (2010). Molecular determinants for PPP2A substrate specificity: Charged residues mediate dephosphorylation by the PP2A/B′ regulatory subunit. Biochemistry 49 (5), 896–995. doi:10.1021/bi902160t

Saurin, A. T. (2018). Kinase and phosphatase cross-talk at the kinetochore. Front. Cell Dev. Biol. 6, 62. doi:10.3389/fcell.2018.00062

Seifried, A., Schultt, J., and Gobla, A. (2013). Human HAD phosphatases: Structure, mechanism, and roles in health and disease. FEBS J. 278 (2), 549–571. doi:10.1111/1742-4658.120633

Shang, L., Henderson, L. B., Cho, M. T., Petrey, D. S., Fong, C. T., Haude, K. M., et al. (2016). De novo nonsense variants in PPP2R5D are associated with intellectual disability, macrocephaly, hypotonia, and autism. Neurogenetics 17 (1), 43–49. doi:10.1007/s10048-015-0466-9

Shi, Y. (2009). Serine/threonine phosphatases: Mechanism through structure. Cell 139 (3), 468–484. doi:10.1016/j.cell.2009.10.006

Toporsian, M., et al. (2021). A disorder-related variant (E420K) of a PPP2A-regulatory subunit (PPP2R5D) causes constitutively active AKT-mTOR signaling and coordinated cell growth. J. Biol. Chem. doi:10.1074/jbc.f2b.2021.100313

Zheng, L., Rong, M., Oberg, E. A., Teng, W., Fong, C. T., Haude, K. M., et al. (2016). De novo nonsense variants in PPP2R5D are associated with intellectual disability, macrocephaly, hypotonia, and autism. Neurogenetics 17 (1), 43–49. doi:10.1007/s10048-015-0466-9

Lambricht, C., Haisen, D., Sents, W., Ivanova, E., and Janssens, V. (2013). Structure, regulation, and pharmacological modulation of PPP2A phosphatases. Methods Mol. Biol. 1053, 283–305. doi:10.1007/978-1-62703-562-0_17

Lange, L., Marks, M., Liu, J., Wittler, L., Bauer, H., Piel, S., et al. (2017). Patternning and gastrulation defects caused by the tw18 lethal are due to loss of Ppp2rta. Biochim. Biophys. Acta 1866 (6), 752–764. doi:10.1016/j.bbamcr.2017.02.005

Lawson, J. E., Niu, X. D., Browning, K. S., Trong, H. L., Yan, J., and Reed, I. J. (1993). Molecular cloning and expression of the catalytic subunit of bovine pyruvate dehydrogenase phosphatase and sequence similarity with Protein Phosphatase 2C. Biochemistry 32 (35), 8987–8993. doi:10.1021/bi00066a002

Lenaerts, L., Reynhout, S., Verbruggen, I., Laumonnier, F., Toutain, A., Bonnet-Brillault, F., et al. (2021). The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction. Genet. Med. 23 (2), 352–362. doi:10.1002/gem.201800984-2
Short, P. J., Mcllroy, J. F., Gallone, G., Sifrim, A., Won, H., Geschwind, D. H., et al. (2018). Defining novel mutations in regulatory elements in neurodevelopmental disorders. Nature 555 (7698), 611–616. doi: 10.1038/nature25983

Sierrecki, E., Sinko, W., McCommon, J. A., and Newton, A. C. (2010). Discovery of small molecule inhibitors of the PH domain leucine-rich repeat protein phosphatase (PILPP) by chemical and virtual screening. J. Med. Chem. 53 (19), 6899–6911. doi: 10.1021/jm100331d

Suleman, J., Al Hashem, A. M., TaBarki, B., Al-Thihli, K., Bi, W., and El-Hattab, A. W. (2018). PPP1R21 homozygous null variants associated with developmental delay, muscle weakness, distinctive facial features, and brain abnormalities. Clin. Genet. 94 (3–4), 351–355. doi: 10.1111/cge.13387

Swingle, M., Ni, L., and Honkanen, R. E. (2007). Small-molecule inhibitors of set/fhr protein phosphatases: Specificity, use and common forms of abuse. Methods Mol. Biol. 365, 23–38. doi: 10.1385/1-59745-267-X:23

Tunks, N. K. (2015). Protein tyrosine phosphatases—from housekeeping enzymes to master regulators of signal transduction. FEBS J. 280 (2), 346–378. doi: 10.1111/febs.12077

Uhlen, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., et al. (2015). Proteomics. Tissue-based map of the human proteome. Science 347 (6220), 1260419. doi: 10.1126/science.1260419

Verbinnen, I., Ferreira, M., and Bollen, M. (2017). Biogenesis and activity regulation of protein phosphatase 1. Biochem. Soc. Trans. 45 (1), 89–90. doi: 10.1042/BST20160154

Verbinnen, I., Vaneynde, P., Reynhoust, S., Lenaerts, L., Derus, R., Hoogv, G., et al. (2023). Protein Phosphatase 2A (PP2A) mutations in brain function, development, and neurologic disease. Biochem. Soc. Trans. 49 (4), 1567–1588. doi: 10.1042/BST20203133

Vissers, L. E. L. M., de Ligt, J., Gilsen, C., Jansen, I., Steenhouver, M., de Vries, P., et al. (2010). A de novo paradigm for mental retardation. Nat. Genet. 42 (12), 1109–1112. doi: 10.1038/ng.917

Vit, G., Duron, J., Rajendraprasad, G., Hertz, E. P. T., Holland, L. K. K., Weisser, M. B., et al. (2022). Chemogenetic profiling reveals PP2A-independent cytotoxicity of proposed PP2A activators iHAP1 and DT-061. EMBO J. 41 (14), e11061. doi: 10.15222/embj.202211061

Walker, I. M., Riboldi, G. M., Drummond, P., Saade-Lemus, S., Martin-Saavedra, J. S., Frucht, S., et al. (2021). PPP2R5D genetic mutations and early-onset parkinsonism. Ann. Neurol. 89 (1), 194–195. doi: 10.1002/ana.25943

Wallace, A., Caruso, P., and Karara, A. (2019). A newborn with severe ventriculomegaly: Expanding the PPP2R1A gene mutation phenotype. J. Pediatr. Genet. 8 (4), 240–243. doi: 10.1055/s-0039-1692141

Wang, L., Wang, X., Chen, J., Yang, Z., Yu, L., Hu, L., et al. (2010). Activation of protein serine/threonine phosphatase PP2Ca efficiently prevents liver fibrosis. PLoS One 5 (12), e14230. doi: 10.1371/journal.pone.0014230

Wiggington, C. P., Roy, J., Damle, N. P., Yadav, V. K., Blikstad, C., Resch, E., et al. (2020). Systematic discovery of short linear motifs decodes calcineurin phosphatase signaling. Mol. Cells 79 (2), 342–358. doi: 10.1007/s11002-020-02618-w

Wright, C. F., McRae, J. F., Clayton, S., Gallone, G., Atkin, S., FitzGerald, T. W., et al. (2018). Making new genetic diagnoses with old data: Iterative reanalysis and reporting from genome-wide data in 1,133 families with developmental disorders. Genet. Med. 20 (10), 1216–1223. doi: 10.1038/gsm.2017.246

Yan, L., Shen, R., Cao, Z., Han, C., Zhang, Y., Liu, Y., et al. (2021). A novel missense variant in the gene PPP2R5D causes a rare neurodevelopmental disorder with increased phenotype. Biomol. Res. Int. 2021, 6661860. doi: 10.1155/2021/6661860

Yeung, K. S., Tso, W. Y. Y., Ip, J. J. K., Mak, C. C. Y., Leung, G. K. C., Tsang, M. H. Y., et al. (2017). Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism. Mol. Autism 8 (1), 66. doi: 10.1186/s13229-017-0182-4

Young, L. C., Hartig, N., Boned Del Rio, I., Sari, S., Ringham-Terry, B., Wainwright, J. R., et al. (2018). SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 115 (45), E10576–E10585. doi: 10.1073/pnas.1720352115

Yu, U. Y., Yoo, B. C., and Ahn, J. H. (2014). Regulatory B subunits of protein phosphatase 2A are involved in site-specific regulation of tau protein phosphorylation. Korans. J. Physiol. Pharmacol. 18 (2), 155–161. doi: 10.4196/kjpp.2014.18.2.155

Zambrano, R. M., Marble, M., Chalew, S. A., Lilje, C., Vargas, A., and Lacassie, Y. (2017). Further evidence that variants in PPP1CB cause a rasopathy similar to Noonan syndrome with loose anagen hair. Am. J. Med. Genet. A 173 (2), 565–567. doi: 10.1002/ajmg.a.38056

Zhang, M., Yogesha, S. D., Mayfield, J. E., Gill, G. N., and Zhang, Y. (2013). Viewing serine/threonine protein phosphatases through the eyes of drug designers. FEBS J. 280 (19), 4739–4760. doi: 10.1111/febs.12481

Zhang, Y., Li, H., Wang, H., Jia, Z., Xi, H., and Mao, X. (2020). A de novo variant identified in the PPP2R1A gene in an infant induces neurodevelopmental abnormalities. Neurosci. Bull. 36 (2), 179–182. doi: 10.11604/jnb.2019-00430-0

Zhou, M., Liu, G., Gao, C., Wang, Y., and Sun, H. (2012). Tissue-specific and nutrient regulation of the branched-chain α-keto acid dehydrogenase phosphatase, protein phosphatase 2Cm (PP2Cm). J. Biol. Chem. 287 (28), 23497–23506. doi: 10.1074/jbc.M111353031

Zhu, Y., Demidov, O. N., Goh, A. M., Virshup, D. M., Lane, D. P., and Bulavin, D. V. (2014). Phosphatase WIP1 regulates adult neurogenesis and WNT signaling during aging. J. Clin. Invest. 124 (7), 3263–3273. doi: 10.1172/JCI73015

Zwaenepoel, K., Louis, J. V., Goris, J., and Janssens, V. (2008). Diversity in genomic organisation, developmental regulation and distribution of the murine PR72/B5 subunits of protein phosphatase 2A. BMC Genomics 9, 393. doi: 10.1186/1471-2164-9-393